Thanks all! CPHD is hot again in the pre-market, & XTRN gets a new patent...
GNLB is close to a 2x from where I/we last bought...
NGEN way up in the pre- market too...
Xtrana Awarded Patent on Xtra Bind Nucleic Acid Extraction Platform
BROOMFIELD, Colo.--(BW HealthWire)--Oct. 10, 2001--Xtrana, Inc. (OTCBB:XTRN - news) announced today the issuance of U.S. patent number 6,291,166 entitled ``Nucleic Acid Archiving.''
This patent covers a family of nucleic acid extraction matrices that Xtrana has developed, representing the foundation technologies for the Company's current and future commercial products. These matrices, called Xtra Bind(TM), capture and stabilize DNA and RNA and allow for enzymatic manipulation of the nucleic acid, resulting in an extremely rapid and efficient extraction protocol.
The Xtra Bind(TM) matrices are unique in that they not only serve to selectively bind DNA and RNA, but also interface with multiple amplification technologies and downstream applications. For example, DNA can be amplified by PCR, and RNA copied and amplified by RT-PCR, directly off of the solid phase bound nucleic acid without elution. This permits an extremely rapid extraction protocol and eliminates the requirement for the vacuum filtration, centrifugation, or hazardous chemicals commonly associated with other extraction methods. The protocol merely requires pipetting or liquid handling steps for the addition of the sample, lysis buffer and a wash buffer -- thus, making it ideally suited for automated platforms and high throughput screening or sample processing.
One of the Xtra Bind matrices is incorporated in Xtra Amp(TM), the Company's DNA or RNA extraction kits that enable high throughput extraction in as little as 3 minutes, versus competing technologies that can take 30 minutes to 3 hours. (My note, and that is a big improvement in speed) A wide variety of applications have been developed, with each kit configured in either twelve 8-tube strips or 96-well plates. Additionally, 384-well plate formats are in development. These products are currently being marketed by various distributors in the United States, Europe, and the Pacific Rim.
The characteristics of Xtra Bind(TM), when combined with the Company's other proprietary technologies in the area of nucleic acid amplification and detection, will allow for the development of rapid, easy-to-use molecular diagnostic device platforms. This family of products is referred to as SCIP(TM). SCIP(TM) products are intended to be turn-key genetic tests that fully integrate DNA or RNA extraction, amplification and detection in small, low complexity devices for use in point-of-care, point-of-service applications. These devices will be targeted for use in clinical diagnostics, the detection of food and water pathogens, and the detection of bacterial warfare agents.
I think that says it all........ |
